196 results on '"Guérin, Annie"'
Search Results
2. Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
3. Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population – a machine learning approach
4. Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States – a retrospective claims analysis
5. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States
6. Institutionalization risk and costs associated with agitation in Alzheimer's disease
7. Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs
8. The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis
9. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States
10. Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists
11. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
12. Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
13. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
14. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD
15. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective
16. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
17. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
18. Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer’s perspective
19. Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)
20. Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
21. Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors
22. Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)
23. Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
24. Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice
25. Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)
26. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
27. Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States
28. Tu1524 PERCEPTION OF MODERATE TO HIGH RISK FACTORS FOR DEVELOPING PRIMARY OVERT HEPATIC ENCEPHALOPATHY ACROSS PHYSICIAN SPECIALTIES IN THE UNITED STATES
29. Tu1522 LONG TERM CARE SERVICES USE AMONG MEDICARE PATIENTS TREATED WITH RIFAXIMIN FOR OVERT HEPATIC ENCEPHALOPATHY
30. Su1546 REAL-WORLD TRENDS IN THE PREVALENCE OF CIRRHOSIS AND RATES OF HEPATIC ENCEPHALOPATHY AMONG ADULTS IN THE UNITED STATES FROM 2006-2020
31. 729 IMPACT OF RIFAXIMIN USE DURING THE 30-DAY POST-DISCHARGE PERIOD FOLLOWING AN OVERT HEPATIC ENCEPHALOPATHY HOSPITALIZATION ON HEALTHCARE UTILIZATION AND COSTS
32. Su1137 SUBOPTIMAL TREATMENT IN PATIENTS WITH CROHN'S DISEASE USING BIOLOGICS
33. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors
34. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
35. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States
36. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage
37. Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)
38. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study
39. En direct de l’essai patrimonial des 42 parcelles d’INRAE à Versailles : impacts de fertilisations centenaires en profondeur du NEOLUVISOL de lœss
40. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
41. Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data
42. Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment
43. Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy
44. Platinaae : plateforme d’ingénieurie en chimie analytique au service de vos recherches
45. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
46. Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
47. Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective
48. Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
49. Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
50. What happens after a single surgical intervention for hidradenitis suppurativa?:A retrospective claims-based analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.